Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

Annals of Oncology

Volumn 12, Issue 1, 2001, Pages 109-114

  Czuczman, M S ^a   Grillo Lopez A J ^b   McLaughlin, P ^c   White, C A ^b   Saleh, M ^d   Gordon, L ^e   LoBuglio, A F ^d   Rosenberg, J ^b   Alkuzweny, B ^b   Maloney, D ^f  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b BIOGEN   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Bcl 2 translocation; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY; NEW DRUG; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BLOOD ANALYSIS; BONE MARROW EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; REFRACTORY PERIOD; TREATMENT OUTCOME;

EID: 0035131919     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008395214584     Document Type: Article

References (29)

1. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma
2. Purification and characterization of the BCL-2 protein
3. Investigation of the subcellular distribution of the BCL-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes
4. Prognostic significance of BCL-2 protein expression in aggressive non-Hodgkin's lymphoma
5. Differentiation of neuroblastoma enhances BCL-2 expression and induces alternations of apoptosis and drug resistance
6. Expression of BCL-2 gene product in neuroblastoma
7. The BCL-2 protein: A prognosis indicator strongly related to p53 protein in lymph node-negative breast cancer patients
8. BCL-2 overexpression and smoking history in head and neck cancer
9. Cancer: Principles & Practice of Oncology
10. Expression of the BCL-2 oncogene protein is not specific for the 14;18 chromosomal translocation
11. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of BCL-2 have residual cells containing the BCL-2 rearrangement at evaluation and after treatment
12. Detection by polymerase chain reaction of residual cells with the BCL-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
13. The clinical significance of molecular response in indolent follicular lymphomas
14. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
15. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
16. Analysis of BCL-2 t(14;18) translocation in relapsed B-cell lymphoma patients treated with the chimeric anti-CD20 antibody IDEC-C2B8
17. IDEC-C2B8 CHOP chemoimmunotherapy in patients with low-grade lymphoma: Interim clinical and BCL-2 (PCR) results
18. Developmental regulation of the BCL-2 protien and susceptibility to cell death in B lymphocytes
19. BCL-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
20. DNA rearrangements in human follicular lymphoma can involve the 5′ or the 3′ region of the BCL-2 gene
21. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow
22. Prognostic value of chromosomal abnormalities in follicular lymphoma
23. Karyotype and prognosis in non-Hodgkin's lymphoma
24. Sequential analysis of 43 patients with non-Hodgkin's lymphoma: Clinical correlations with cytogenetics, histologic, immunophenotyping, and molecular studies
25. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
26. Rituximab clearance of BCL-2 from peripheral blood (PB) and bone marrow (BM) from patients (PTS) with relapsed low-grade follicular lymphoma (LG/F NHL)
27. IDEC-C2B8 clears BCL-2(t 14;18) in patients with relapsed low-grade or follicular lymphoma
28. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
29. Chimeric anti-CD20 (IDC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs